Statins (for CVD Prevention)

Statins represent one of the most extensively studied and evidence-backed interventions for cardiovascular disease prevention. Research indicates these HMG-CoA reductase inhibitors significantly reduce LDL cholesterol levels by 30-50% and lower cardiovascular events by approximately 20-30% across diverse populations. Multiple landmark trials including the Heart Protection Study, WOSCOPS, and JUPITER have demonstrated consistent benefits for both primary and secondary prevention of heart attacks, strokes, and cardiovascular mortality.

Studies suggest statins work through both cholesterol-dependent and independent mechanisms, with anti-inflammatory effects and endothelial protection contributing to their cardiovascular benefits. The evidence base spans over 150 randomized controlled trials involving more than 400,000 participants, establishing statins as a cornerstone of modern cardiovascular medicine. Research indicates benefits extend across age groups, including elderly patients over 75 years old.

While generally well-tolerated, studies show statins carry risks including muscle-related side effects (myalgia in 5-10% of users, rare but serious rhabdomyolysis), potential diabetes risk increase, and occasional liver enzyme elevations. Research suggests these risks are generally outweighed by cardiovascular benefits in appropriate candidates, though individual risk-benefit assessment remains important. The intervention requires prescription monitoring and is contraindicated in pregnancy and certain liver conditions.